Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.

9077Background: Osimertinib is approved for metastatic NSCLC patients with EGFR T790M mutation after progression from EGFR-TKI therapy. Despite impressive tumor responses, drug resistance usually d...